Logo image of ALKS

ALKERMES PLC (ALKS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ALKS - IE00B56GVS15 - Common Stock

29.58 USD
-0.14 (-0.47%)
Last: 11/28/2025, 8:12:24 PM
29.36 USD
-0.22 (-0.74%)
After Hours: 11/28/2025, 8:12:24 PM
Fundamental Rating

6

Overall ALKS gets a fundamental rating of 6 out of 10. We evaluated ALKS against 534 industry peers in the Biotechnology industry. ALKS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ALKS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

ALKS had positive earnings in the past year.
In the past year ALKS had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ALKS reported negative net income in multiple years.
ALKS had a positive operating cash flow in each of the past 5 years.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

Looking at the Return On Assets, with a value of 14.57%, ALKS belongs to the top of the industry, outperforming 95.13% of the companies in the same industry.
ALKS has a better Return On Equity (19.58%) than 95.88% of its industry peers.
ALKS has a Return On Invested Capital of 16.22%. This is amongst the best in the industry. ALKS outperforms 96.44% of its industry peers.
Industry RankSector Rank
ROA 14.57%
ROE 19.58%
ROIC 16.22%
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

With an excellent Profit Margin value of 22.30%, ALKS belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
ALKS has a better Operating Margin (23.59%) than 95.69% of its industry peers.
Looking at the Gross Margin, with a value of 86.04%, ALKS belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.
ALKS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.59%
PM (TTM) 22.3%
GM 86.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

ALKS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for ALKS has been reduced compared to 1 year ago.
The number of shares outstanding for ALKS has been increased compared to 5 years ago.
There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

ALKS has an Altman-Z score of 6.26. This indicates that ALKS is financially healthy and has little risk of bankruptcy at the moment.
ALKS has a better Altman-Z score (6.26) than 75.84% of its industry peers.
There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.26
ROIC/WACC2.11
WACC7.68%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

ALKS has a Current Ratio of 3.67. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ALKS (3.67) is comparable to the rest of the industry.
A Quick Ratio of 3.27 indicates that ALKS has no problem at all paying its short term obligations.
ALKS has a Quick ratio of 3.27. This is comparable to the rest of the industry: ALKS outperforms 42.13% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.27
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

4

3. Growth

3.1 Past

ALKS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.71%, which is quite good.
Measured over the past years, ALKS shows a very strong growth in Earnings Per Share. The EPS has been growing by 32.50% on average per year.
ALKS shows a small growth in Revenue. In the last year, the Revenue has grown by 1.08%.
Measured over the past years, ALKS shows a small growth in Revenue. The Revenue has been growing by 5.87% on average per year.
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%

3.2 Future

Based on estimates for the next years, ALKS will show a decrease in Earnings Per Share. The EPS will decrease by -1.55% on average per year.
The Revenue is expected to grow by 7.72% on average over the next years.
EPS Next Y-48.02%
EPS Next 2Y-31.39%
EPS Next 3Y-19.38%
EPS Next 5Y-1.55%
Revenue Next Year-2.6%
Revenue Next 2Y10.16%
Revenue Next 3Y6.82%
Revenue Next 5Y7.72%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3 4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 11.93, the valuation of ALKS can be described as reasonable.
Based on the Price/Earnings ratio, ALKS is valued cheaply inside the industry as 96.63% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.31. ALKS is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 21.67 indicates a rather expensive valuation of ALKS.
93.07% of the companies in the same industry are more expensive than ALKS, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.56, ALKS is valued a bit cheaper.
Industry RankSector Rank
PE 11.93
Fwd PE 21.67
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALKS is valued cheaply inside the industry as 97.38% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ALKS is valued cheaply inside the industry as 98.31% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.94
EV/EBITDA 8.42
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The decent profitability rating of ALKS may justify a higher PE ratio.
ALKS's earnings are expected to decrease with -19.38% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.37
EPS Next 2Y-31.39%
EPS Next 3Y-19.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALKS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALKERMES PLC

NASDAQ:ALKS (11/28/2025, 8:12:24 PM)

After market: 29.36 -0.22 (-0.74%)

29.58

-0.14 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners104.46%
Inst Owner Change8.97%
Ins Owners1.66%
Ins Owner Change1.24%
Market Cap4.88B
Revenue(TTM)1.52B
Net Income(TTM)339.32M
Analysts80.91
Price Target44.43 (50.2%)
Short Float %9.85%
Short Ratio6.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.1%
Min EPS beat(2)59.84%
Max EPS beat(2)72.36%
EPS beat(4)4
Avg EPS beat(4)43.68%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)4
Avg EPS beat(8)10.27%
EPS beat(12)8
Avg EPS beat(12)42.89%
EPS beat(16)11
Avg EPS beat(16)151.46%
Revenue beat(2)2
Avg Revenue beat(2)10.32%
Min Revenue beat(2)8.51%
Max Revenue beat(2)12.13%
Revenue beat(4)3
Avg Revenue beat(4)7.62%
Min Revenue beat(4)-1.19%
Max Revenue beat(4)12.13%
Revenue beat(8)4
Avg Revenue beat(8)3.11%
Revenue beat(12)7
Avg Revenue beat(12)3.8%
Revenue beat(16)10
Avg Revenue beat(16)3.09%
PT rev (1m)-0.39%
PT rev (3m)3.72%
EPS NQ rev (1m)-0.82%
EPS NQ rev (3m)0.56%
EPS NY rev (1m)16.08%
EPS NY rev (3m)17.59%
Revenue NQ rev (1m)2.32%
Revenue NQ rev (3m)2.45%
Revenue NY rev (1m)3.24%
Revenue NY rev (3m)3.24%
Valuation
Industry RankSector Rank
PE 11.93
Fwd PE 21.67
P/S 3.21
P/FCF 9.94
P/OCF 9.03
P/B 2.82
P/tB 2.96
EV/EBITDA 8.42
EPS(TTM)2.48
EY8.38%
EPS(NY)1.37
Fwd EY4.61%
FCF(TTM)2.98
FCFY10.06%
OCF(TTM)3.27
OCFY11.07%
SpS9.21
BVpS10.5
TBVpS9.99
PEG (NY)N/A
PEG (5Y)0.37
Graham Number24.2
Profitability
Industry RankSector Rank
ROA 14.57%
ROE 19.58%
ROCE 19.34%
ROIC 16.22%
ROICexc 40.45%
ROICexgc 45.58%
OM 23.59%
PM (TTM) 22.3%
GM 86.04%
FCFM 32.29%
ROA(3y)8.82%
ROA(5y)3.68%
ROE(3y)13.16%
ROE(5y)4.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5Y-0.08%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 163.07%
Cap/Sales 3.25%
Interest Coverage 250
Cash Conversion 138.93%
Profit Quality 144.77%
Current Ratio 3.67
Quick Ratio 3.27
Altman-Z 6.26
F-Score6
WACC7.68%
ROIC/WACC2.11
Cap/Depr(3y)76.88%
Cap/Depr(5y)63.55%
Cap/Sales(3y)2.83%
Cap/Sales(5y)2.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.71%
EPS 3Y54.92%
EPS 5Y32.5%
EPS Q2Q%-31.94%
EPS Next Y-48.02%
EPS Next 2Y-31.39%
EPS Next 3Y-19.38%
EPS Next 5Y-1.55%
Revenue 1Y (TTM)1.08%
Revenue growth 3Y9.89%
Revenue growth 5Y5.87%
Sales Q2Q%4.24%
Revenue Next Year-2.6%
Revenue Next 2Y10.16%
Revenue Next 3Y6.82%
Revenue Next 5Y7.72%
EBIT growth 1Y-17.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.49%
EBIT Next 3Y-3.56%
EBIT Next 5Y14.79%
FCF growth 1Y93.4%
FCF growth 3Y76.56%
FCF growth 5YN/A
OCF growth 1Y83.22%
OCF growth 3Y62.84%
OCF growth 5Y43.53%

ALKERMES PLC / ALKS FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status for ALKS stock?

ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


What is the valuation of ALKERMES PLC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ALKERMES PLC (ALKS) is 11.93 and the Price/Book (PB) ratio is 2.82.


What is the expected EPS growth for ALKERMES PLC (ALKS) stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -48.02% in the next year.